Autologous Platelet-Released Growth Factor and Sexual Dysfunction Amendment: A Pilot Clinical Trial of Successful Improvement Sexual Dysfunction after Pelvic Irradiation

摘要

Sexual dysfunction (SDF) is a common sequel to cancer treatment which affects the quality of life in womentreated with pelvic radiotherapy. The aim of this study was to evaluate the safety, symptom resolution and objectiveimprovement the injection of autologous platelet released growth factor (APRGF) for treatment of SDF in cited patients.This prospective pilot study enrolled 10 cancer-free patients with SDF who underwent pelvic radiotherapy at least 5years ago, randomly. Each patient was received 1-2 cc APRGF within four weeks and all patients were re-evaluatedat eight weeks and six months. CD34 immuno histochemistry and Masson’s trichrome staining were performed onvaginal biopsy section for angiogenesis and fibrosis assay respectively. Sexual satisfaction after the injection of APRFGwas clinically difference and the entire patient had sexual satisfaction. In the patient’s follow-up, none of them needsto repeat the treatment. Our results declared that APRGF injection was effective and symptoms were disappeared inthe entire patients. Significant objective improvements in vaginal diameter (mean before injection, 6.5 cm vs 7.1 cmafter injection) (p-value = 0.001) and vaginal flexibility (mean before treatment, 0.72 cm vs 1.85 cm after injection)(P-value = 0.026) were observed. Characteristics of discharge before the injection in 60% of patients were includeddry vagina and 40% had mild discharge but after injection 40% of patients had moderate and also 60% had mild andsufficient discharge (P-value= 0.190). Overally, our patients reported better sexual function and showed better vaginalfunction indexes, after APRFG injection.